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Cardiac fibrosis is a common pathological change associated with cardiac injuries and
diseases. Even though the accumulation of collagens and other extracellular matrix
(ECM) proteins may have some protective effects in certain situations, prolonged fibrosis
usually negatively affects cardiac function and often leads to deleterious consequences.
While the development of cardiac fibrosis involves several cell types, the major source
of ECM proteins is cardiac fibroblast. The high plasticity of cardiac fibroblasts enables
them to quickly change their behaviors in response to injury and transition between
several differentiation states. However, the study of cardiac fibroblasts in vivo was very
difficult due to the lack of specific research tools. The development of cardiac fibroblast
lineage-tracing mouse lines has greatly promoted cardiac fibrosis research. In this article,
we review the recent cardiac fibroblast lineage-tracing studies exploring the origin of
cardiac fibroblasts and their complicated roles in cardiac fibrosis, and briefly discuss the
translational potential of basic cardiac fibroblast researches.
Keywords: cardiac fibroblast, lineage-tracing, fibrosis, heart, cardiac disease

INTRODUCTION
Cardiac fibrosis is commonly associated with cardiovascular diseases (CVDs), the leading cause of
death in western countries. In the United States, the direct health expenditures and lost productivity
associated with CVDs in 2010 was estimated to be $315.4 billion (Go et al., 2014). Cardiac
fibrosis is mainly present in two forms which are replacement fibrosis and interstitial fibrosis.
Replacement fibrosis is characterized by the formation of collagenous scar tissue replacing the
dead cardiomyocytes, which is often observed after myocardial infarction (MI) (Segura et al.,
2014). Interstitial fibrosis, in contrast, usually does not involve massive cardiomyocyte death
and is characterized by the accumulation of ECM proteins in the interstitial space between
cardiomyocytes, which may be caused by pressure overload and infection (Fenoglio et al., 1983;
Creemers and Pinto, 2010). In both forms of cardiac fibrosis, the activation of cardiac fibroblasts is
involved (Ivey et al., 2018). The mechanical stress and inflammation stimulate cardiac fibroblast
proliferation and promote their differentiation into myofibroblasts with elevated expression of
ECM proteins (Ivey and Tallquist, 2016; Tallquist and Molkentin, 2017). Besides the accumulated
ECM which stiffens the heart, the fibrotic tissue and activated fibroblasts also affect the contraction
of adjacent cardiomyocytes, leading to the reduction of cardiac function (Kong et al., 2014).
However, despite the deleterious effects of fibrosis on cardiac function, the accumulated ECM and
myofibroblasts filled with stress fibers may play an important role in maintaining tissue integrity
especially when a substantial death of cardiomyocytes occurs (Talman and Ruskoaho, 2016).
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express Tcf21, WT1, and Tbx18, while Tie2 expression has only
been identified in endocardial cardiac fibroblast progenitors.
Studies have also reported cell surface markers of fibroblasts,
which are important due to their potential use in cell sorting
(Smith et al., 2011; Asli et al., 2019). Among these identified
cell surface markers, platelet-derived growth factor receptor
alpha (PDGFRα) is the most widely used that is abundantly
expressed in fibroblasts found in various tissues (Smith et al.,
2011; Asli et al., 2019). Other cell surface markers that have
been reported to be expressed by fibroblasts include NG2 and
PDGFRβ which, however, are primarily expressed in pericytes
which are fibroblast-like cells associated with blood vessels
(Chen et al., 2016).

In addition, cardiac fibroblasts may also regulate cardiac function
through cross-talking with other cell types residing in the
heart such as cardiomyocytes (Zhang et al., 2012) and immune
cells (Van Linthout et al., 2014). Due to the complicated role
of cardiac fibroblasts in the diseased heart, manipulation of
cardiac fibroblast activities to promote their beneficial effects
and limit their deleterious effects is needed, which requires a
complete understanding of the regulation of cardiac fibroblast
activities. The development of cardiac fibroblast lineage-tracing
mouse lines promoted researches addressing many fundamental
questions about cardiac fibroblast. This review summarizes the
recent advances in cardiac fibroblast lineage-tracing and the
findings resulted from researches utilizing these tools. The
clinical implication of cardiac fibroblast lineage-tracing studies is
also briefly discussed.

CARDIAC FIBROBLAST MARKERS

CARDIAC FIBROBLAST
LINEAGE-TRACING SYSTEMS AND
TOOLS

By definition, fibroblasts are a group of cells secreting collagen
and other ECM proteins. They reside in the interstitial spaces
between tissue parenchymal cells. Under basal conditions, these
cells stay mostly quiescent and likely play important roles in
maintaining the interstitial connective tissue and mediating the
communication between surrounding cells (Ivey and Tallquist,
2016; Tallquist and Molkentin, 2017). Under stressed conditions,
their production of ECM proteins significantly increases, which
is responsible for the formation of fibrotic tissue (Souders
et al., 2009; Ivey and Tallquist, 2016; Tallquist and Molkentin,
2017). Thus, many identified fibroblast markers are ECM
proteins. Some ECM proteins highly expressed by fibroblasts
are fibrillar collagens such as collagen I and collagen III and
fibronectin (Carver et al., 1991; Philips et al., 1994). The
expression of these ECM proteins significantly increases after the
differentiation of cardiac fibroblasts into myofibroblasts (Baum
and Duffy, 2011). In addition, myofibroblasts express some
unique ECM proteins such as periostin (Conway and Molkentin,
2008; Shimazaki et al., 2008), and ECM remodeling enzymes
such as matrix metalloproteases (MMPs), tissue inhibitors of
metalloproteinases (TIMPs), and lysyl oxidase (LOX) (Polyakova
et al., 2004; Brown et al., 2007; Fan et al., 2012; Lindner
et al., 2012; El Hajj et al., 2017). Similar to other types of
cells, a cytoskeletal network is present in fibroblasts. While
many components in this network are common proteins also
expressed in other cell types, some of them have been used as
fibroblast markers due to their unique expression in fibroblasts.
Vimentin, an intermediate filament protein, is abundant in
both quiescent fibroblasts and myofibroblasts (Wang et al.,
2003; Baum and Duffy, 2011). In contrast, smooth muscle
α-actin (αSMA, encoded by Acta2) is exclusively expressed
after myofibroblast differentiation (Leslie et al., 1991). Another
group of fibroblast markers are transcription factors that are
specifically expressed in fibroblasts. Transcription factors that
have been used as cardiac fibroblast markers include Tcf21,
WT1, Tbx18, and Tie2 (Quaggin et al., 1999; Cai et al., 2008;
Zeisberg and Kalluri, 2010; Zhou and Pu, 2012; Moore-Morris
et al., 2014). Developmentally, epicardial fibroblast progenitors

The definition of lineage-tracing is the identification of all
progeny of a single cell or cell population. The principle of
lineage-tracing is that the expression of reporter genes under
the control of the cis-regulatory elements of a gene that is
specifically expressed in a cell type permits the identification of
this cell population and its descendants. Thus, the identification
of fibroblast markers has facilitated the development of some
fibroblast lineage-tracing tools. However, not all previously
identified fibroblast markers are suitable for fibroblast lineagetracing because most of those markers are not exclusive to
cardiac fibroblasts. The currently widely used lineage-tracing
systems can be classified into two categories. The first category
utilizes a reporter gene, such as GFP, directly controlled by
a tissue-specific promoter or locus, which is referred to as
direct lineage-tracing in this article. The reporter gene can be
introduced into the genome as a transgene together with a
tissue-specific promoter or inserted into a tissue-specific locus
(knock-in) (Hamilton et al., 2003; LeBleu et al., 2013). The other
category employs the Cre-loxP recombination system (Sauer,
1998) which includes two components, a Cre recombinase (Cre)
gene driven by a tissue-specific promoter/locus and a reporter
gene downstream of a stop codon flanked by two loxP sites
(Soriano, 1999). The expression of Cre induces the deletion
of the stop codon between the two loxP sites, leading to the
expression of the reporter gene, which is thus referred to as
indirect lineage-tracing. Similarly, Cre can be introduced into the
genome together with a tissue-specific promoter as a transgene
or knocked into a specific tissue-specific locus. In the Cre-loxP
system, the reporter gene is usually inserted into the ROSA26
locus and under the control of a strong promoter (Madisen
et al., 2010). Multiple Cre isoforms have been developed by
different researchers. While the original Cre becomes active
once being expressed (Soriano, 1999), the Cre mutants fused
to one (CreERT and CreERT2) or two (MerCreMer) mutated
murine estrogen-binding domains are only active when bound
to 4-hydroxy-tamoxifen (Metzger et al., 1995; Zhang et al.,
1996; Indra et al., 1999). CreERT2 is the second generation
of tamoxifen-inducible Cre developed based on CreERT and is
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the browning of adipose tissue in female mice (Zhao et al., 2019),
likely due to its anti-estrogenic activity, which may affect the
experimental results.
As mentioned previously in this article, both the reporter
gene in the direct lineage-tracing system and the Cre in the
indirect lineage-tracing system can be introduced into the animal
together with the promoter as a transgene randomly inserted
into the genome or specifically knocked into a locus that is
only active in certain cell type. Some examples of the mouse
lines generated using the transgene strategy are αSMA-RFP
(Magness et al., 2004), Col1a1-GFP (Kalajzic et al., 2002; Yata
et al., 2003), Col1a2-CreERT (Ubil et al., 2014), Col1a1-CreERT2
(Biswas, 2016), Tie2-Cre (Kisanuki et al., 2001), and αSMACreERT2 (Wendling et al., 2009). The major advantage of the
transgene strategy is that it is relatively simple to generate a
lineage-tracing mouse line in this way. However, the efficiency
and reliability of these lines vary significantly. The reason
is that the included promoter may lack certain regulatory
elements. For example, among the 3 Col1a1-GFP mouse lines,
only the one containing the collagen gene promoter (−3122
to +111) and upstream DNase I-hypersensitive sites has been
shown to specifically and efficiently label cardiac fibroblasts
(Yata et al., 2003), while GFP expression was absent in the
heart of the other Col1a1-GFP mouse lines (Kalajzic et al.,
2002). Moreover, αSMA-CreERT2 efficiently induced reporter
expression in cardiac myofibroblast after MI (Fu et al., 2018),
however, the αSMA-RFP mouse line failed to do so (personal
experience). In addition, the random insertion of the transgene
may disrupt endogenous gene expression causing unintended
mutation. In contrast, the knock-in strategy usually allows
the precise control of the reporter or Cre expression by the
endogenous tissue-specific locus, which is desired in most
lineage-tracing studies. Examples of cardiac fibroblast lineagetracing mouse lines created using this strategy include PostnCreERT2 (Kaur et al., 2016), Tbx18-Cre (Cai et al., 2008),
Tbx18-CreERT2 (Moore-Morris et al., 2014), Tcf21-Cre (Acharya
et al., 2011), Tcf21-MerCreMer (Acharya et al., 2011), PostnMerCreMer (Kanisicak et al., 2016), WT1-Cre (Moore-Morris
et al., 2014), and WT1-CreERT2 (Ali et al., 2014; Moore-Morris
et al., 2014). However, the knock-in of the Cre also abolishes
the expression of the endogenous gene expression from the
disrupted allele. Even though homozygous knockout can be
avoided through genotyping, the heterozygous knockout may
also have a milder effect.
Recently, the Dre-rox, a system similar to Cre-loxP
(Anastassiadis et al., 2009), has been applied in lineage-tracing
studies of cardiac fibroblasts and other cell types (He et al., 2017;
Pu et al., 2018). The expression of Dre induces the recombination
of rox sites, resulting in the expression or knockout of a gene.
In addition to the original Dre allele, Dre fused to murine
estrogen-binding domains has also being generated, which
enables tamoxifen-dependent Dre activity (He et al., 2017).
More important, due to the high specificity of Cre-loxP and
Dre-rox systems, the dual lineage-tracing combining these two
systems is a recent trend in lineage-tracing studies. Mice carrying
both Cre-loxP and Dre-rox permit the simultaneous tracing of
two distinct or related cell types (Liu et al., 2019). These mice

more sensitive to 4-hydroxy-tamoxifen as compared to CreERT
(Indra et al., 1999). The MerCreMer mediates more stringent
recombination likely because each MerCreMer requires two,
rather than one, 4-hydroxy-tamoxifen molecules for activation
(Verrou et al., 1999).
The major advantage of the direct control of the report
gene expression by a tissue-specific promoter/locus is that the
expression level of the reporter usually reflects the promoter
activity, which enables the tracking of the expression of the tissuespecific gene. However, when the activity of the tissue-specific
promoter is low, the expression of the reporter may not be
strong enough for certain experiments. In addition, the activity
of some promoters or loci may totally disappear or start in a
particular developmental or disease stage. Thus, the reporterlabeled cells identified at a time point may not be the same
population of cells observed at an earlier time point or their
descendants. Examples of this system include αSMA-RFP mice
(Magness et al., 2004), Col1a1-GFP mice (Kalajzic et al., 2002;
Yata et al., 2003), Tcf21-lacZ (Quaggin et al., 1999), Pdgfra-GFP
(Hamilton et al., 2003), and Postn-lacZ (Snider et al., 2008).
In contrast to the direct lineage-tracing system, one common
advantage of the indirect lineage-tracing system is that the
expression of the reporter in a cell and all its descendants is
permanent once the recombination has taken place regardless of
the change in the activity of the promoter driving the Cre, which
is favored in some studies. Lineage-tracing mouse lines of this
category that have been used in cardiac fibroblast studies include
Acta2-CreERT2 (Wendling et al., 2009), Col1a2-CreERT (Ubil
et al., 2014), Col1a1-CreERT2 (Biswas, 2016), Postn-CreERT2
(Kaur et al., 2016), Tbx18-Cre (Cai et al., 2008), Tbx18-CreERT2
(Moore-Morris et al., 2014), Tcf21-Cre (Acharya et al., 2011),
Tcf21-MerCreMer (Acharya et al., 2011), Tie2-Cre (Kisanuki et al.,
2001), Sox9-CreER (He et al., 2017), WT1-Cre (Moore-Morris
et al., 2014), and WT1-CreERT2 (Ali et al., 2014; Moore-Morris
et al., 2014). The choice between a non-inducible Cre and an
inducible Cre depends on the goal of the study. A unique
feature of the lineage-tracing system using non-inducible Cre
is that the reporter expression starts once the promoter driving
the Cre becomes active. This can be an advantage in some
developmental studies focusing on the fate of cells derived from
an embryonic lineage. However, such a feature can be a problem
in some studies aimed at lineage-tracing cells expressing a certain
gene at a particular time point as some of the lineage-traced
cells observed in non-inducible Cre lines may be a result of a
previous recombination and may no longer express the gene
whose promoter drives the Cre, which may lead to a false
conclusion. The inducible Cre, on the other hand, allows the
timely control of recombination. A drawback of the inducible
Cre is the lower recombination efficiency as compared with
non-inducible Cre. Repeated or continuous tamoxifen treatment
is required to induce sufficient recombination. However, some
side effects associated with tamoxifen have been reported and
may affect the experimental result. In particular, tamoxifen
often induces dystocia when applied to pregnant female mice
(Narver, 2012). The retrieval of the pups requires cesarean
sections which are very labor-intense. Moreover, it has been
shown that tamoxifen can induce physiological changes such as
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epithelial-to-mesenchymal transition (EMT) around embryonic
day 14.5 (E14.5). Disruption of PDGFRα, Wt1, or Tcf21 signaling
caused significantly defects in this process (Moore et al., 1999;
Smith et al., 2011; Acharya et al., 2012). The requirement
of Tbx18 in this process, however, has not been revealed.
Using the Tie2-Cre lineage-tracing mouse line, it was shown
that some cardiac fibroblasts were derived from endocardium
through the endothelial-to-mesenchymal transition (EndoMT)
(Kisanuki et al., 2001; Ali et al., 2014). In mouse heart, the
EndoMT process of Tie2 lineage-traced endocardial cells first
starts around E11.5 day in the outflow septum (Kisanuki
et al., 2001). It was estimated that around 85% of cardiac
fibroblasts are derived from epicardial cells, while the other
∼15% are derived from endothelial cells (Moore-Morris et al.,
2014). Moreover, a difference in the spatial distribution of these
two cardiac fibroblast subpopulations has been noticed. While
endocardium-derived cardiac fibroblasts are more prevalent in
the interventricular septum, the ones derived from epicardium
are more dominant in the left ventricular free wall (Moore-Morris
et al., 2014). It is worth noting that the Wt1-Cre mice and Tie2Cre mice used in this study also labeled cardiomyocytes and
endothelial cells, respectively. Moreover, experiments treating
adult Tcf21-MerCreMer, WT1-CreERT2, and Tbx18-CreERT2
mice with tamoxifen showed that only Tcf21 was still expressed
in adult cardiac fibroblast while the lineage-traced cells in WT1CreERT2 and Tbx18-CreERT2 mice were primarily epicardial
cells (Moore-Morris et al., 2014), indicating the limitations of
some of these lines.

may be particularly useful in the study of cardiac fibroblast
differentiation and transdifferentiation when the precursor cells
and their descendants express different marker genes.
Besides the use of cardiac fibroblast lineage-tracing mouse
lines to understand the origin of cardiac fibroblasts and their
cell fate changes in response to cardiac injuries, an equally,
if not more, important application of these tools is the
study of mechanisms regulating cardiac fibroblast activities
after injuries and their therapeutic potentials. When cross-bred
with a mouse line carrying a gene with its essential exon(s)
flanked by loxP sites or a Cre-dependent gene overexpression
cassette containing a 50 loxP-flanked stop sequence, cardiac
fibroblast-specific knockout or overexpression of the gene can
be achieved in vivo. Importantly, even though many of the
aforementioned Cre lines have been utilized to study the cardiac
fibroblast-specific functions of genes, they do have different
advantages and limitations largely due to the variation in the
activities of promoters driving Cre expression. For example.
Tcf21-MerCreMer mouse line has been successfully employed
to lineage-trace cardiac fibroblasts during development and in
normal hearts and study cardiac fibroblast differentiation after
cardiac injuries (Acharya et al., 2011; Kanisicak et al., 2016;
Khalil et al., 2017; Ivey et al., 2018). However, the ability of
this line to specifically induce gene knockout or overexpression
in myofibroblasts may be limited as the expression of Tcf21 in
cardiac fibroblasts dramatically decreases during myofibroblast
differentiation (Fu et al., 2018). As a result, pre-injury tamoxifen
treatment to mouse lines carrying Tcf21-MerCreMer is usually
required for successful and efficient recombination (Khalil et al.,
2017; Xiang et al., 2017). However, the myofibroblast-specific
expression of the target genes may render pre-injury tamoxifen
treatment less efficient in these lines, as the condensed chromatin
may reduce the accessibility of Cre to loxP sites in the genes
that are not being actively expressed. In contrast, mouse lines
such as Postn-MerCreMer and Col1a2-CreERT2 are likely more
efficient in inducing gene knockout and overexpression in
myofibroblasts due to their high level of expression in these
cells (Fu et al., 2018). And combining two Cre lines, such
as Tcf21-MerCreMer and Postn-MerCreMer may grant more
efficient and complete recombination in cardiac fibroblasts of
different states.

CARDIAC FIBROBLAST ORIGIN IN THE
DISEASED HEART
Many heart diseases trigger cardiac fibrosis. Both interstitial
fibrosis and replacement fibrosis involves the activation of
cardiac fibroblasts and their differentiation into myofibroblasts.
As the major fibroblast lineages in the normal heart, it is not
a surprise that endocardium and epicardium-derived resident
cardiac fibroblasts are also the major contributors to the cardiac
myofibroblast population in the injured heart (Ali et al., 2014;
Moore-Morris et al., 2014; Kanisicak et al., 2016; Fu et al., 2018).
Dramatic changes in cellular composition happen in the diseased
heart. A question asked by many researchers is whether epicardial
and endocardial cells in the adult heart still have the ability to
transdifferentiate into cardiac fibroblasts in response to injury.
While earlier studies suggested the existence of EMT in the adult
heart (van Tuyn et al., 2007; Russell et al., 2011; Zhou and Pu,
2011; Duan et al., 2012), careful lineage-tracing studies using
WT1-CreERT2 and Tbx18-CreERT2 mouse lines found that the
adult epicardial cells do not give rise to cardiac fibroblasts after
cardiac injury (Ali et al., 2014; Moore-Morris et al., 2014). In
contrast, the study of the EndoMT of Tie2 lineage-traced cells
in the injured adult heart is still missing. This is largely due to
the limitation of the Tie2-Cre mouse line (Kisanuki et al., 2001;
Ali et al., 2014). Interestingly, in contrast to Tcf21 lineage-traced
cardiac fibroblasts which all differentiated into myofibroblasts
expressing Postn in response to injury (Kanisicak et al., 2016;

THE DEVELOPMENTAL ORIGIN OF
CARDIAC FIBROBLASTS
One of the most important fundamental questions about cardiac
fibroblasts is their developmental origin. Studies utilizing Tcf21
(Tcf21-MerCreMer), Wt1 (Wt1-Cre), and Tbx18 (Tbx18-Cre)
cis-regulatory elements-controlled lineage-tracing mouse lines
have shown that epicardial progenitors give rise to both cardiac
fibroblasts and vascular smooth muscle cells developmentally
(Cai et al., 2008; Zhou et al., 2008; Smith et al., 2011;
Acharya et al., 2012; Moore-Morris et al., 2014), which is
consistent with earlier experiments conducted using chick
embryos (Mikawa and Gourdie, 1996). In mice, these epicardial
cardiac fibroblast progenitors express PDGFRα and start the
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Fu et al., 2018), a study using another endothelial/endocardial
lineage-tracing mouse line, Cdh5-Cre, found that less than 1%
of Cdh5 lineage-traced cells (including both endothelial cells
and endothelium-derived cardiac fibroblasts) expressed Postn
after MI (Kanisicak et al., 2016), suggesting a difference in
the transcriptomic regulation of cardiac fibroblasts of different
origins. It is possible that the EndoMT taken place in some of
the endothelial/endocardial cells during development is actually
a partial EndoMT, causing an incomplete cell fate change (Li
et al., 2018). However, a definitive answer about EndMT in
the adult heart requires inducible endothelial lineage-tracing
mouse lines such as Tie2-CreERT2 and Cdh5-CreERT mice,
both of which are available now (Wang et al., 2010; Maliken
et al., 2018). The hematopoietic cell is another cell type that
has been reported to transdifferentiate into cardiac fibroblasts
in response to ischemic injury. Bone marrow transplantation
experiments showed that bone marrow-derived cells positive
for collagen I and αSMA were present in the infarct (Haudek
et al., 2006; Möllmann et al., 2006; van Amerongen et al., 2008;
Verma et al., 2017). However, studies using hematopoietic cell
lineage-tracing mouse lines found that these cells minimally
contributed to the cardiac fibroblast population (Ali et al., 2014;
Moore-Morris et al., 2014; Kanisicak et al., 2016), suggesting
that this transdifferentiation is a rather rare event. It is possible
that the bone marrow-derived fibroblasts identified in the
recipient mice in bone marrow transplantation experiments were
actually derived from transplanted bone marrow mesenchymal
progenitor cells instead of hematopoietic cells as myofibroblast
differentiation of bone marrow mesenchymal progenitor cells has
been reported (Quante et al., 2011). Thus, further lineage-tracing
studies of bone marrow mesenchymal progenitor cells is required
to answer this question.

partial transcriptomic switch to chondrocyte (Fu et al., 2018).
Removal of matrifibrocytes from infarct scar by cryoinjury
caused a reduction in cardiac function and exacerbation of
dilation, suggesting an important function of matrifibrocytes
in maintaining the infarct stability (Fu et al., 2018). However,
mechanisms responsible for matrifibrocyte differentiation are
still not clear. Another study found that in mouse lines
susceptible to injury-induced myocardial calcification, Col1a2
lineage-traced cardiac fibroblasts differentiated into a calciumdepositing cell type similar to osteoblast, a process believed
to be mediated by Runx2, an osteogenic transcription factor
(Pillai et al., 2017). Moreover, it was recently shown that
Tcf21 lineage-traced cardiac fibroblasts differentiated into
adipocytes in response to a high-fat diet (HFD), which is
normally inhibited by cardiomyocyte-secreted prokineticin2 (Qureshi et al., 2017), further suggesting the plasticity
of these cells. The transdifferentiation of cardiac fibroblasts
into endothelial cells upon MI has also been investigated.
It was reported that ∼35% of Col1a2 lineage-traced cardiac
fibroblasts expressed endothelial markers such as VECAD
and contributed to the neovascularization in injured hearts
(Ubil et al., 2014), suggesting a novel therapeutic role of
cardiac fibroblasts. However, the study conducted by another
group using multiple cardiac fibroblast lineage-tracing lines
including the same Col1a2-CreERT mouse line showed that
the neovascularization process was mainly mediated by the
expansion of pre-existing endothelial cells but not cardiac
fibroblasts (He et al., 2017). The contradictory results of the
two studies may be partially due to the difference in the
markers and antibodies used for endothelial cell identification.
A study using a dual lineage-tracing system may help clarify
this contradiction.

CARDIAC FIBROBLAST PLASTICITY

TARGETING CARDIAC FIBROBLASTS TO
TREAT HEART DISEASES

In general, the fibroblast is a very plastic cell type. The
differentiation of cardiac fibroblasts into myofibroblast has
been verified by many groups using multiple cardiac fibroblast
lineage-tracing lines (Ali et al., 2014; Moore-Morris et al., 2014;
Kanisicak et al., 2016; Khalil et al., 2017; Fu et al., 2018).
The transcriptional regulation of myofibroblast differentiation
is very complicated as many signaling pathways including
TGFβ and novel mechanisms have been revealed (see section
“Targeting Cardiac Fibroblasts to Treat Heart Diseases” for more
detailed discussion). It was once believed that myofibroblasts
were terminal-differentiated and were cleared by apoptosis
once the infarct scar was stabilized, which was evidenced by
the disappearance of αSMA+ myofibroblasts (Takemura et al.,
1998). However, our recent lineage-tracing study showed that
Tcf21 lineage-traced cardiac fibroblasts persisted in infarct scar
beyond 8 weeks after MI (Fu et al., 2018). Myofibroblasts in
stabilized infarct scar further differentiated into matrifibrocytes
which did not express αSMA and only expressed low levels
of typical myocardial ECM proteins such as collagen 1
and collagen 3 (Fu et al., 2018). Instead, matrifibrocytes
expressed a high level of cartilage ECM proteins, suggesting a

Frontiers in Physiology | www.frontiersin.org

An ultimate goal of cardiac fibroblast lineage-tracing is to
treat heart diseases through manipulating cardiac fibroblast
activities. This requires the understanding of the functions of
genes expressed in cardiac fibroblasts and their roles in disease
development. These studies have been greatly promoted by CreloxP-mediated cardiac fibroblast lineage-tracing mouse lines,
which allows specific knockout and overexpression of genes in
cardiac fibroblasts in vivo without affecting other tissues/cell
types (see Table 1 for a summary of recent relevant studies).

Targeting TGFβ and Related Signaling
The correlation between TGFβ signaling and cardiac fibrosis
has long been noticed (Casscells et al., 1990). Only recently,
with the help of cardiac fibroblast lineage-tracing and specific
gene knockout, many details in this process have been
revealed in vivo. Using Tcf21-MerCreMer and Postn-MerCreMermediated cardiac fibroblast-specific knockout of Tgfbr1/2 Smad2
and Smad3, which are important components of canonical
TGFβ signaling, we found that in cardiac fibroblast canonical
TGFβ signaling played an important role in activating cardiac
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TABLE 1 | Summarization of recent findings by employing Cre-loxP-mediated cardiac fibroblast-specific gene deletion or overexpression mouse lines.
Injury model

Changes in cardiac fibroblasts

Impact on cardiac function and
phenotype

References

Tcf21-MerCreMer;
Postn-MerCreMer

Tgfbr1/2 double deletion;
Smad2/3 single and double
deletion

TAC

Reduced myofibroblast
proliferation, differentiation,
contraction, and ECM protein
expression

Improved function (Tgfbr1/2
deletion only); reduced fibrosis (all
except Smad2 deletion)

Khalil et al., 2017

Tcf21-MerCreMer;
Postn-MerCreMer

Ctnnb1 deletion

TAC

Increased ECM gene expression

Improved function; reduced fibrosis

Xiang et al., 2017

Tcf21-MerCreMer

Pkr1 deletion

HFD

Increased adipogenesis

Reduced function

Qureshi et al., 2017

Tcf21-MerCreMer

Fn1 deletion

I/R

Reduced myofibroblast number

Improved function; reduced fibrosis
and cardiomyocyte hypertrophy

Valiente-Alandi et al., 2018

Tcf21-MerCreMer

Loxl2 deletion

TAC

Reduced TGF-β2 production and
myofibroblast differentiation

Improved function; reduced fibrosis

Yang et al., 2016

Tcf21-MerCreMer

Lats1/2 double deletion

None

Spontaneous myofibroblast
differentiation

Reduced function; increased
fibrosis

Xiao et al., 2019

Postn-MerCreMer

Tgfbr2 deletion

Mouse model of
proteotoxic cardiac disease

Reduced myofibroblast number

Improved function and survival rate;
reduced cardiomyocyte
hypertrophy

Bhandary et al., 2018

Postn-MerCreMer

Tgfbr2 deletion

Mouse model of cardiac
myosin binding protein
c-induced cardiomyopathy

Reduced myofibroblast number

Improved function and survival rate;
reduced fibrosis

Meng et al., 2018

Postn-MerCreMer

Mapk14 deletion

MI; I/R

Reduced myofibroblast
differentiation and expansion

Improved function; reduced fibrosis

Molkentin et al., 2017

Postn-MerCreMer

Ccn2 deletion

Ang II infusion

Attenuated TGFβ-induced
myofibroblast differentiation

Reduced fibrosis

Dorn et al., 2018

Postn-MerCreMer

Hsp47 deletion

TAC; MI

Reduced collagen production

Improved function (TAC); reduced
fibrosis (TAC and MI); increased
rupture (MI); reduced function (MI)

Khalil et al., 2019

Postn-MerCreMer

Grk2 deletion

I/R

Reduced myofibroblast
differentiation

Improved function; reduced fibrosis

Travers et al., 2017

Postn-Cre

Smad2 and Smad3
deletion

MI; I/R

Enhanced proliferation;
disorganized stress fibers (Smad3
deletion)

Temporary improved of function
(Smad2 deletion); exacerbated
long-term function and enchanced
ECM maladaptive remodeling
(Smad3 deletion)

Kong et al., 2018; Huang
et al., 2019
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TABLE 1 | Continued

7

Cre lines used

Genes deleted or
overexpressed

Injury model

Changes in cardiac fibroblasts

Impact on cardiac function and
phenotype

References

Postn-Cre

Rock2 deletion; Rock2
overexpression

Ang II infusion

Reduced myofibroblast phenotype
(Rock 2 deletion vs. overexpression)

Improved function and reduced
fibrosis (Rock 2 deletion vs.
overexpression)

Shimizu et al., 2017

Postn-Cre

Pkd1 deletion

I/R; MI

Attenuated TGFβ-induced
myofibroblast differentiation

Reduced scar size; increased
cardiomyocyte hypertrophy

Villalobos et al., 2019

Postn-Cre

Il17ra deletion

MI

Reduced granulocyte macrophage
colony-stimulating factor+
(GM-CSF+ ) fibroblast

Increased survival rate; reduced
infarct size

Chen et al., 2018

Postn-Cre

Klf5 deletion

TAC

Reduced IGF-1 secretion

Improved function; reduced
cardiomyocyte hypertrophy

Takeda et al., 2010

Postn-Cre

Sox9 deletion

MI

Reduced myofibroblast phenotype

Improved function; reduced dilation
and scar size

Scharf et al., 2019

Postn-Cre

miR-33 deletion

TAC

Reduced proliferation and lipid raft
content

Reduced fibrosis

Nishiga et al., 2017; Dorn
et al., 2018

Col1a2-CreERT

Atf3 overexpression

Ang II infusion

Reduced p38 activation

Improved function; reduced fibrosis

Li et al., 2017

Col1a2-CreERT

Il1r1 deletion

MI

Reduced IL-1α–induced Il6, Mmp3,
and Mmp9 expression

Improved function; reduced fibrosis

Bageghni et al., 2019

Col1a2-CreERT

Il11 overexpression

None

Increased myofibroblast
differentiation

Reduced function; increased
fibrosis

Schafer et al., 2017

Col1a2-CreERT

Grk2 deletion

I/R

Reduced TNFα secretion

Improved function; reduced fibrosis
and inflammation

Woodall et al., 2016

Col1a2-CreERT

Mcu deletion

MI; Ang II infusion

Increased myofibroblast
differentiation

Reduced function; increased
fibrosis

Lombardi et al., 2019

Studies were grouped based on Cre mouse lines used.
Cardiac Fibroblast Lineage-Tracing
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differentiation (Mori et al., 1999; Shi-wen et al., 2006).
Interestingly, despite the fact that cardiomyocyte is the major
source of CTGF in the heart, the deletion of Ccn2 (the gene
encoding CTGF) in cardiomyocytes failed to protect the heart
from pressure overload-induced cardiomyopathy (Accornero
et al., 2015). A later study found that CTGF functioned
as an autocrine factor in cardiac fibroblasts and cardiac
fibroblast-specific deletion of Ccn2 significantly improved cardiac
function after Ang II infusion (Dorn et al., 2018). It was
demonstrated that Wnt signaling and TGFβ signaling also
cross-talk during myofibroblast differentiation (Chen et al.,
2011; Akhmetshina et al., 2012). The elevated level of TGFβ
in injured myocardium activated Wnt signaling which led
to cardiac fibrosis in experimental autoimmune myocarditis
(Blyszczuk et al., 2016). In a recent study specifically deleting
Ctnnb1 (the gene encoding β-catenin) in cardiac fibroblasts,
the cardiac function and fibrosis were found to be improved,
which was primarily due to reduced ECM protein secretion
by cardiac fibroblasts (Xiang et al., 2017). Moreover, it
was recently found that canonical TGFβ signaling during
myofibroblast differentiation of cardiac fibroblasts required
functional primary cilia in cardiac fibroblasts. When primary
cilium is disrupted in cardiac fibroblasts due to cardiac fibroblastspecific Pkd1 deletion, the TGFβ-Smad3 signaling-induced
ECM protein production and myofibroblast differentiation of
cardiac fibroblasts were impaired, leading to insufficient scar
formation and increased cardiomyocyte hypertrophy after MI
(Villalobos et al., 2019). Interleukin (IL) is an important
group of inflammatory cytokines. Multiple IL receptors are
expressed in cardiac fibroblasts, which regulates myofibroblast
activities (Shinde and Frangogiannis, 2014; Turner, 2014; Francis
Stuart et al., 2016). Using cardiac fibroblast-specific Cre lines,
it was found that blocking the effects of proinflammatory
ILs on cardiac fibroblasts through cardiac fibroblast-specific
deletion of IL receptors, Il1r1 (Bageghni et al., 2019) or Il17ra
(Chen et al., 2018), both alleviated injury-induced cardiac
fibrosis and cardiac function reduction. Interestingly, in both
studies, cardiac fibroblast-specific deletion of IL receptor genes
reduced the infiltration/activity of immune cells in the injured
heart, suggesting that cardiac fibroblasts play an important
role in the regulation of post-injury inflammation, which is
mediated by IL signaling. In contrast, overexpressing Il11,
whose expression in fibroblasts is activated by TGFβ, in cardiac
fibroblasts caused spontaneous cardiac fibrosis without injury
(Schafer et al., 2017).

fibroblasts, which was mainly mediated by Smad3 but not Smad2
(Khalil et al., 2017). Interestingly, even though both cardiac
fibroblast-specific deletion of Tgfbr1/2 and Smad2/3 significantly
reduced cardiac fibrosis induced by transverse aortic constriction
(TAC), only the deletion of Tgfbr1/2 in cardiac fibroblasts
ameliorated cardiac hypertrophy and resulted in a functional
improvement at 4 and 12 weeks after TAC (Khalil et al., 2017).
Similarly, myofibroblast-specific Tgfbr2 deletion led to improved
cardiac function in mouse models of proteotoxic cardiac disease
and cardiac myosin binding protein C-induced cardiomyopathy
(Bhandary et al., 2018; Meng et al., 2018). Studies conducted by
another group using Postn-Cre-mediated myofibroblast-specific
deletion of Smad3 and Smad2 found that while deletion of
Smad2 temporarily improved cardiac function around 7 days
after myocardial infarct (MI) in mice, deletion of Smad3 caused a
reduction in cardiac function 28 days after MI (Kong et al., 2018;
Huang et al., 2019). The identified difference between Smad2 and
Smad3 deletion was likely because of the differential regulation
of myofibroblast and collagen matrix organization by Smad2 and
Smad3 (Kong et al., 2018; Huang et al., 2019; Russo et al., 2019).
The limited controversies in the effect of Smad gene deletion
on cardiac function reported in these studies were possibly due
to the different injury models used in which the expression
of Smad2/3 in cardiac fibroblasts may have different effects
on cardiac function. Moreover, the phenotypic and functional
differences between mice with cardiac fibroblast-specific deletion
of Tgfbr1/2 and Smad2/3 suggest that non-canonical TGFβ
signaling also plays an important role in cardiac fibroblastmediated post-injury remodeling (Khalil et al., 2017). Indeed,
using the same cardiac fibroblast-specific Cre lines, the role of
TGFβ-MAPK kinase 6 (MKK6)-p38 signaling in myofibroblast
differentiation of cardiac fibroblasts was revealed (Molkentin
et al., 2017). Cardiac fibroblast-specific deletion of Mapk14
(the gene encoding p38) significantly reduced myofibroblast
expansion and cardiac fibrosis and improved cardiac function
after ischemia/reperfusion (I/R) in mice (Molkentin et al., 2017).
A similar protective effect was observed in mice with cardiac
fibroblast-specific deletion of Atf3, a transcription factor that
activates the expression of Map2k3, a p38 kinase (Li et al., 2017).
Besides, the TGFβ-RhoA-Rock pathway has also been found
to play an important role in the actin stress fiber formation,
which is essential for myofibroblast differentiation (Bhowmick
et al., 2001; Shi and Massagué, 2003; Costanza et al., 2017).
A study found that in angiotensin II (Ang II) infusion-induced
cardiomyopathy, the myofibroblast-specific deletion of Rock2
significantly reduced αSMA expression in these cells, together
with reduced connective tissue growth factor (CTGF) and FGF2
expression in cardiac fibroblasts, and improved cardiac function
and fibrosis (Shimizu et al., 2017). However, how the disrupted
stress fiber formation led to reduced cytokine production is
still not clear.
Besides the direct regulatory roles of canonical and noncanonical TGFβ signaling in the myofibroblast differentiation
of cardiac fibroblasts and cardiac fibrosis, the cross-talk
between TGFβ signaling and other signaling pathways has
also been studied using fibroblast-specific Cre mouse lines.
CTGF is an important mediator in TGFβ-induced myofibroblast
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Direct Targeting ECM
Being one of the most important characteristics of the fibroblast,
the direct regulation of collagen secretion and ECM remodeling
in fibroblast is also an important research target. Collagen is first
secreted from cells in the form of procollagen. In vitro studies
identified that the secretion of procollagen required HSP47, a
stress-inducible chaperone protein (Nagata et al., 1988; Satoh
et al., 1996; Ishida et al., 2006). As expected, the deletion of Hsp47
in cardiac fibroblasts specifically reduced collagen production but
not the general paracrine secretory activity (Khalil et al., 2019).
Cardiac fibroblast-specific Hsp47 deletion significantly reduced
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identified. Krüppel-like factor 5 (Klf5) is a transcription factor
regulating cell differentiation and animal development (Dang
et al., 2000; Bieker, 2001; Black et al., 2001). The Nagai group
recently reported that the global heterozygous knockout of
Klf5 reduced cardiac hypertrophy and fibrosis induced by Ang
II infusion (Shindo et al., 2002). A later study conducted
by the same group found that cardiac fibroblast-specific Klf5
deletion ameliorated cardiac hypertrophy induced by moderateintensity pressure overload, which, however, was not observed
in cardiomyocyte-specific Klf5 knockout mice (Takeda et al.,
2010). It was found that KLF5 activated IGF-1 secretion from
cardiac fibroblasts, which then served as the mediator in the
crosstalk between cardiac fibroblasts and cardiomyocytes (Takeda
et al., 2010). Another recent study combining TOMO-seq and
transcription factor binding site analysis identified SOX9 as a
potential novel transcription factor activating the expression of
fibrotic genes in the heart (Lacraz et al., 2017), which might
explain the amelioration in MI-induced cardiac dysfunction,
fibrosis, and dilation in mice with cardiac fibroblast-specific
deletion of Sox9 (Scharf et al., 2019).

cardiac fibrosis and improved heart diastolic function after TAC.
However, the reduced collagen accumulation in these mice led
to an increase in lethality after MI, owing to the insufficient
scar formation (Khalil et al., 2019). This study strongly suggests
that the effect of cardiac fibroblast-mediated fibrotic response
after cardiac injury can vary significantly among different
injury types. While the beneficial effect of fibrotic tissue may
outweigh its deleterious effect after an acute injury that causes
massive cardiomyocyte death, the effect of interstitial fibrosis in
chronic cardiomyopathy may be largely detrimental. Fibronectin
is another abundant ECM protein in the heart. Its level in
the heart increases significantly after injuries (Heling et al.,
2000; Dobaczewski et al., 2006; van Dijk et al., 2008). Cardiac
fibroblast-specific Fn1 deletion led to improved cardiac function,
reduced cardiac fibroblast activity, and attenuated cardiac fibrosis
and hypertrophy after I/R (Valiente-Alandi et al., 2018), which
was likely related to the function of fibronectin in collagen
assembly (Sottile et al., 2007). The post-injury ECM remodeling
involves collagen crosslinking, which is primarily mediated by
isoforms of lysyl oxidases (LOXs). Yang et al. (2016) identified
a specific increase in lysyl oxidase-like 2 (LOXL2) level after
TAC. Cardiac fibroblast-specific deletion of Loxl2 significantly
improved TAC-induced cardiac function (Yang et al., 2016).
Interestingly, besides the expected reduction in fibrosis, the
production of TGFβ2 was also reduced in cardiac fibroblasts
lacking Loxl2, which was found to be mediated by PI3K/AKT
signaling (Yang et al., 2016).

Epigenetic Regulation
The study of epigenetic regulation of myofibroblast
differentiation and cardiac fibrosis has also benefited from
cardiac fibroblast-specific Cre lines. It was recently found
that a metabolic switch to glycolysis during myofibroblast
differentiation due to the shutdown of mitochondrial calcium
uniporter complex increased the production of α-ketoglutarate
which then enabled histone demethylation at myofibroblast
gene loci, promoting myofibroblast differentiation (Lombardi
et al., 2019). Deletion of mitochondrial calcium uniporter
(Mcu) in fibroblasts, blocked mitochondria calcium influx, and
therefore promoted the metabolic switch. As a result, cardiac
fibroblast-specific deletion of Mcu attenuated myofibroblast
differentiation and improved cardiac function after cardiac
injury (Lombardi et al., 2019). Moreover, another study found
that microRNA, miR-33 regulated cholesterol metabolic gene
expression in cardiac fibroblasts, which was important for cardiac
fibroblast proliferation. Cardiac fibroblasts lacking miR-33 had
reduced proliferation due to altered lipid raft cholesterol content.
Postn-Cre-induced deletion of miR-33 in mice led to decreased
cardiac fibrosis (Nishiga et al., 2017).

A Re-look at Cardiomyocyte-Expressed
Genes
Previous research focusing on cardiomyocytes revealed
the cardiomyocyte-specific functions of many genes. The
development of cardiac fibroblast-specific gene deletion and
overexpression strategies has recently permitted the study of
these genes in cardiac fibroblasts. The function of G proteincoupled receptors (GPCRs) in the pathological changes of
cardiomyocytes after injuries has been studied extensively
(Koch et al., 1995; Raake et al., 2008; Schumacher et al., 2015).
However, the role of GPCRs in cardiac fibroblast-mediated
fibrosis was only revealed recently. It was reported that cardiac
fibroblast-specific deletion of Grk2 (G protein-coupled receptor
kinase 2) reduced the secretion of TNFα by cardiac fibroblasts
and cardiac fibrosis after I/R, together with improved cardiac
function (Woodall et al., 2016; Travers et al., 2017). Moreover,
the function of Hippo pathway, which is known for its inhibitory
effect on cardiomyocyte proliferation (Halder and Johnson, 2011;
Leach et al., 2017), in cardiac fibroblasts was studied (Xiao et al.,
2019). It was found that cardiac fibroblast-specific deletion of
Hippo pathway kinases, Lats1 and Lats2, caused spontaneous
myofibroblast differentiation (Xiao et al., 2019). This mechanistic
study identified that Yap directly activated myofibroblast genes,
which was blocked by the phosphorylation of Yap by Lats1/2.

THE CLINICAL IMPLICATION OF
CARDIAC FIBROBLAST
LINEAGE-TRACING
Studies have shown that simply depleting cardiac fibroblasts
from the heart after an injury usually causes detrimental effects
(Kanisicak et al., 2016; Fu et al., 2018). More and more evidence
generated using cardiac fibroblast lineage-tracing tools and
cardiac fibroblast-specific Cre lines have suggested an increasing
number of cardiac fibroblast-expressed genes as potential targets
for treating cardiac diseases. Thus, manipulation of the cardiac
fibroblast gene expression profile may be a feasible approach.
Systemic delivery of traditional medication that regulates the

Novel Transcription Factors
Using cardiac fibroblast-specific Cre lines, novel transcription
factors regulating cardiac fibroblast activities have also been
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other. Moreover, due to difference in the effect of fibrosis on
cardiac tissue healing and function after different cardiac injuries
indicated in recent studies (Khalil et al., 2019), more work
comparing the effects of the cardiac fibroblast-specific knockout
and overexpression of the same genes in different disease/injury
models are also needed. These studies are particularly important
for the selection of appropriate treatment target. In addition, the
current mechanistic understanding of the plasticity of cardiac
fibroblasts is largely limited to myofibroblast differentiation.
Signaling pathways regulating other differentiation potentials
of cardiac fibroblasts may also deserve more attention because
of the increased evidences of these differentiations in diseased
hearts. In addition, even though many of the cardiac fibroblast
lineage-tracing tools have shown high fibroblast-specificity in
the heart, most of the promoters/loci used in these cardiac
fibroblast lineage-tracing tools are also active in fibroblasts and
similar cell types residing in other organs (Quaggin et al.,
1999; Kanisicak et al., 2016). Thus, further studies are required
to engineer those promoters/loci to achieve absolute cardiac
fibroblast-specificity, which is required for the specific regulation
of target genes in cardiac fibroblasts in gene therapy. However,
considering the relatively short history of the modern lineagetracing system, it is expected that the progress of this research
area will further accelerate. In summary, the advances in cardiac
fibroblast lineage-tracing studies and their potential application
in gene therapy may shed light on novel treatment approaches
for cardiac diseases.

expression of certain genes or the activity of relevant signaling
pathways has been tested in clinical trials for cardiac fibrosis
treatment, which, however, usually indiscriminately targets all
the cells in the body and has unintended targets, often leading
to severe side effects. For instance, animal studies have shown
the anti-cardiac fibrosis effects of TGFβ inhibitors such as
pirfenidone and tranilast (Edgley et al., 2012). However, a
hepatic adverse effect was identified in a clinical trial testing
the therapeutic effect of tranilast in restenosis caused by
percutaneous coronary intervention (Holmes et al., 2002). The
development of gene therapies, especially the adeno-associated
virus (AAV)-mediated gene therapy (Finer and Glorioso, 2017),
has now made it possible to specifically manipulate gene
expression in certain cell types. Dependent on the transgene
selected, gene therapy allows both direct overexpression and
knockdown of a certain gene in the cell (Eaton et al., 2002;
Chadderton et al., 2009; Samulski and Muzyczka, 2014). Over
the years, different AAV serotypes that specifically target different
organs have been reported (Wu et al., 2006). A greater specificity
has been achieved using cell type-specific promoters to drive
the expression of transgenes (Peel et al., 1997; Dashkoff et al.,
2016; Hanlon et al., 2017). Using this approach, multiple groups
have reported successful specific expression of transgenes in
cardiomyocytes (Aikawa et al., 2002; Pleger et al., 2007; Pacak
et al., 2008). Recently, AAV carrying a Postn promoter-driven
transgene has also been used to specifically induce transgene
expression in myofibroblasts in the heart (Piras et al., 2016),
strongly suggesting a bright future of this treatment strategy.
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The great plasticity of cardiac fibroblasts allows them to quickly
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the alteration and remodeling of the myocardial environment.
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to reveal the developmental origin of cardiac fibroblasts and
their differentiation pathways in injuries and diseases. Even
though an increasing number of signaling pathways have been
suggested to play a role in the regulation of cardiac fibroblast
activities and differentiation, more studies are still required to
reveal the details of these regulations, such as how these signaling
pathways specifically regulate the beneficial and deleterious
effects of cardiac fibroblasts and how they crosstalk with each
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